FDA accepts Teva's application for Uzedy for bipolar I disorder
The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
FDA accepts Teva & Medincell’s UZEDY sNDA for extended-release to treat BP-I
Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...
Hosted on MSN1d
Global Suicides; Drug Overdose Deaths Drop; Keto Diet for Bipolar Disorder?
The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...
Teva, Medincell announce FDA acceptance of sNDA for Uzedy
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
Pharmabiz1d
Teva Pharma, Medincell announce US FDA acceptance of sNDA for Uzedy to treat people living with schizophrenia
Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...
The Pharma Letter2d
FDA accepts Teva and Medincell’s Uzedy sNDA
Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...
Morningstar1mon
Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
Morningstar brands and products Company Portfolio ...
Pharm Exec1d
FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder
The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...
Yahoo Finance1mon
Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
Teva 2024 Results earnings conference call today at 8:00am ET, webcast and replay: https://events.q4inc.com/attendee/899170090 * NDA (New Drug Application): Formal ...
Investing2d
FDA accepts Teva, Medincell's supplemental application for UZEDY as bipolar I disorder treatment
UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...
ADVFN8d
Medincell: UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies ...